Julius Knowles

Novalar Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on dental products. The company's OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. The company was founded in 2000 and is headquartered in San Diego, CA.

X-BODY, Inc. provides biotechnological research services. The company was founded on April 9, 2009 and is headquartered in Waltham, MA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Mass General Brigham Ventures LLC (Mass General Brigham Ventures) is a venture capital subsidiary of Partners Research Ventures & Licensing founded in 2005. The firm is headquartered in the Cambridge, Massachusetts.

Partners Innovation Fund LLC, an Evergreen Fund, invests in companies located in the US. The fund targets companies operating in the fields of healthcare sector. It provides financing for seed and early stage capital requirements. It also makes follow on investments.